Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
BLTE
Stock Latest News
Ratings
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential
10d ago
BLTE
Premium
Ratings
Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations
17d ago
BLTE
Premium
Company Announcements
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant
17d ago
6K
BLTE
Premium
The Fly
Belite Bio completes enrollment in PHOENIX trial
17d ago
BLTE
Premium
The Fly
Belite Bio management to meet with Maxim
2M ago
BLTE
Premium
Ratings
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating
2M ago
BLTE
Premium
Ratings
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress
2M ago
BLTE
Premium
Company Announcements
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease
2M ago
6K
BLTE
Premium
The Fly
Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA
2M ago
BLTE
Premium
Company Announcements
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength
2M ago
BLTE
Premium
Ratings
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio
2M ago
BLTE
Premium
Company Announcements
Belite Bio Advances Clinical Trials Amid Financial Challenges
2M ago
BLTE
Premium
Company Announcements
Belite Bio Advances Tinlarebant Trials with Positive Interim Results
2M ago
6K
BLTE
Premium
The Fly
Belite Bio reports Q1 EPS (27c), consensus (37c)
2M ago
BLTE
Premium
The Fly
Belite Bio reports Q1 EPS (45c), consensus (37c)
2M ago
BLTE
Premium
Company Announcements
Belite Bio Announces Key Resolutions from 2025 General Meeting
3M ago
6K
BLTE
Premium
The Fly
Needham healthcare analysts hold analyst/industry conference call
4M ago
JNJ
NVS
Premium
Company Announcements
Belite Bio, Inc. Appoints New Auditor
4M ago
6K
BLTE
Premium
The Fly
Belite Bio price target raised to $80 from $79 at Benchmark
4M ago
BLTE
Premium
Ratings
Belite Bio, Inc. ADR: Promising Clinical Progress and Strong Financial Position Drive Buy Rating
4M ago
BLTE
Premium
Ratings
Promising Pipeline and Strategic Advancements: Marc Goodman Recommends ‘Buy’ for Belite Bio, Inc.
4M ago
BLTE
Premium
Company Announcements
Belite Bio’s Earnings Call: Cautious Optimism Amid Progress
4M ago
BLTE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.